STOCK TITAN

Takeda (TAK) director Steven Gillis details share and RSU holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Takeda Pharmaceutical Co. Ltd. director Steven Gillis filed an initial Form 3 reporting his beneficial holdings. He directly holds 9,700 Ordinary Shares and 15,857 American Depositary Shares.

He also reports several equity-based awards. Tax Obligation Awards are each economically equivalent to one Ordinary Share and, upon vesting, will be settled in cash primarily to cover tax obligations at the then-current market price of the Ordinary Shares. A separate Cash Settled Retirement Award consists of restricted stock units that pay cash equal to the value of one Ordinary Share at vesting, which occurs upon his retirement from the board. Another RSU award will convert into Ordinary Shares, then into an equivalent number of American Depositary Shares as it vests on June 1, 2026 (3,100 Ordinary Shares), June 1, 2027 (3,400 Ordinary Shares) and June 1, 2028 (3,200 Ordinary Shares).

Positive

  • None.

Negative

  • None.
Insider GILLIS STEVEN
Role Director
Type Security Shares Price Value
holding Tax Obligation Award -- -- --
holding Tax Obligation Award -- -- --
holding Tax Obligation Award -- -- --
holding Cash Settled Retirement Award -- -- --
holding Ordinary Shares -- -- --
holding American Depositary Shares -- -- --
Holdings After Transaction: Tax Obligation Award — 1,152 shares (Direct); Cash Settled Retirement Award — 2,356 shares (Direct); Ordinary Shares — 9,700 shares (Direct); American Depositary Shares — 15,857 shares (Direct)
Footnotes (1)
  1. Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on the following schedule: June 1, 2026 (3,100 ordinary shares), June 1, 2027 (3,400 ordinary shares) and June 1, 2028 (3,200 ordinary shares). Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive a cash amount equivalent to the value of one Ordinary Share at the time of vest. The RSUs vest upon the director's retirement from the board.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
GILLIS STEVEN

(Last)(First)(Middle)
8755 W. HIGGINS ROAD
SUITE 1025

(Street)
CHICAGO ILLINOIS 60631

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares9,700(1)D
American Depositary Shares15,857D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Tax Obligation Award06/01/202606/01/2026Ordinary Shares1,152(2)D
Tax Obligation Award06/01/202706/01/2027Ordinary Shares1,192(2)D
Tax Obligation Award06/01/202806/01/2028Ordinary Shares1,180(2)D
Cash Settled Retirement Award (3) (3)Ordinary Shares2,356(3)D
Explanation of Responses:
1. Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on the following schedule: June 1, 2026 (3,100 ordinary shares), June 1, 2027 (3,400 ordinary shares) and June 1, 2028 (3,200 ordinary shares).
2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
3. Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive a cash amount equivalent to the value of one Ordinary Share at the time of vest. The RSUs vest upon the director's retirement from the board.
Remarks:
Exhibit 24 Power of Attorney
/s/ Max Heuer, by power of attorney, for Steven Gillis03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Steven Gillis report owning in Takeda (TAK) on this Form 3?

He reports direct holdings of 9,700 Ordinary Shares and 15,857 American Depositary Shares. In addition, he lists multiple equity-based awards, including Tax Obligation Awards and cash-settled restricted stock units tied to the value of Takeda Ordinary Shares.

What are the Tax Obligation Awards reported by Steven Gillis at Takeda (TAK)?

Each Tax Obligation Award is economically equivalent to one Ordinary Share and settles in cash. Upon vesting, it converts into a cash payment primarily designed to cover tax obligations, using the then-current market price of the Takeda Ordinary Shares.

How do Steven Gillis’s RSUs in Takeda (TAK) vest over time?

One RSU award vests in tranches on June 1, 2026, 2027 and 2028. It covers 3,100 Ordinary Shares in 2026, 3,400 in 2027 and 3,200 in 2028, then converts into an equivalent number of American Depositary Shares after vesting.

What is the Cash Settled Retirement Award reported by Steven Gillis at Takeda (TAK)?

The Cash Settled Retirement Award is an RSU grant paid entirely in cash. Each unit represents the value of one Ordinary Share, and the award vests when Gillis retires from the board, providing a cash amount based on the share value at that time.

Does this Takeda (TAK) Form 3 show any insider share purchases or sales?

The Form 3 functions as an initial ownership report and does not show explicit buys or sells. All entries are classified as holdings, with unknown transaction codes and no open-market purchase or sale activity indicated in the summarized data.

How are Steven Gillis’s RSUs in Takeda (TAK) ultimately settled?

Different RSU types settle either in shares or cash. One RSU award converts into Ordinary Shares and then American Depositary Shares after vesting, while Tax Obligation Awards and the Cash Settled Retirement Award pay cash amounts linked to the value of Takeda Ordinary Shares.
Takeda Pharm

NYSE:TAK

View TAK Stock Overview

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

57.06B
3.16B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo